Biomarker Predicts Breast Cancer Risk in Asymptomatic Women
|
By LabMedica International staff writers Posted on 18 Apr 2016 |
|
In healthy breast tissue, the percentage of cells expressing molecular marker Ki67 (green) and p27 (red) was low (Photo courtesy of Sung Jin Huh, Harvard Medical School).
A biomarker has been identified that may allow clinicians to predict the risk of an asymptomatic woman eventually developing breast cancer.
To identify this disease indicator, investigators at Harvard Medical School studied the association between breast cancer risk and the frequency of mammary epithelial cells expressing the proteins p27 (Cyclin-dependent kinase inhibitor 1B), estrogen receptor (ER), and Ki67 (Marker of proliferation Ki-67) in normal breast tissue from 302 women (69 breast cancer cases, 233 controls) who had been initially diagnosed with benign breast disease.
Immunofluorescence assays for p27, ER, and Ki67 were performed on tissue microarrays constructed from benign biopsies containing normal mammary epithelium and scored by computational image analysis.
Results revealed that the frequency of Ki67+ cells was positively associated with breast cancer risk among premenopausal women. Conversely, the frequency of ER+ or p27+ cells was inversely, but not significantly, associated with subsequent breast cancer risk. Notably, high Ki67+/low p27+ and high Ki67+/low ER+ cell frequencies were significantly associated with a five-fold higher risk of breast cancer compared with low Ki67+/low p27+ and low Ki67+/low ER+ cell frequencies, respectively, among premenopausal women.
This data suggests that the fraction of actively cycling cells in normal breast tissue may represent a marker for breast cancer risk assessment, which may therefore impact the frequency of screening procedures in at-risk women.
"Currently, we are not able to do a very good job at distinguishing women at high and low risk of breast cancer," said senior author Dr. Rulla Tamimi, associate professor of epidemiology at Harvard Medical School. "By identifying women at high risk of breast cancer, we can better develop individualized screening and also target risk reducing strategies."
The study was published in the April 1, 2016, issue of the journal Cancer Research.
Related Links:
Harvard Medical School
To identify this disease indicator, investigators at Harvard Medical School studied the association between breast cancer risk and the frequency of mammary epithelial cells expressing the proteins p27 (Cyclin-dependent kinase inhibitor 1B), estrogen receptor (ER), and Ki67 (Marker of proliferation Ki-67) in normal breast tissue from 302 women (69 breast cancer cases, 233 controls) who had been initially diagnosed with benign breast disease.
Immunofluorescence assays for p27, ER, and Ki67 were performed on tissue microarrays constructed from benign biopsies containing normal mammary epithelium and scored by computational image analysis.
Results revealed that the frequency of Ki67+ cells was positively associated with breast cancer risk among premenopausal women. Conversely, the frequency of ER+ or p27+ cells was inversely, but not significantly, associated with subsequent breast cancer risk. Notably, high Ki67+/low p27+ and high Ki67+/low ER+ cell frequencies were significantly associated with a five-fold higher risk of breast cancer compared with low Ki67+/low p27+ and low Ki67+/low ER+ cell frequencies, respectively, among premenopausal women.
This data suggests that the fraction of actively cycling cells in normal breast tissue may represent a marker for breast cancer risk assessment, which may therefore impact the frequency of screening procedures in at-risk women.
"Currently, we are not able to do a very good job at distinguishing women at high and low risk of breast cancer," said senior author Dr. Rulla Tamimi, associate professor of epidemiology at Harvard Medical School. "By identifying women at high risk of breast cancer, we can better develop individualized screening and also target risk reducing strategies."
The study was published in the April 1, 2016, issue of the journal Cancer Research.
Related Links:
Harvard Medical School
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Latest Pathology News
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read more
Molecular Diagnostics
view channel
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
Natera (Austin, TX, USA) presented findings from 25 abstracts, including nine oral presentations, at the ESMO Congress 2026 in Madrid. The research examined circulating tumor DNA (ctDNA) testing for molecular... Read more
Hematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
Immunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read more
Microbiology
view channel
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Technology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read more
Industry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more
